


Solid-State Properties of Pharmaceutical Materials

Stephen R. Byrn • George Zografi • Xiaoming (Sean) Chen



WILEY

SOLID-STATE PROPERTIES OF PHARMACEUTICAL MATERIALS

**STEPHEN R. BYRN
GEORGE ZOGRAFI
XIAOMING (SEAN) CHEN**

WILEY

This edition first published 2017
© 2017 John Wiley & Sons, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Stephen R. Byrn, George Zografi and Xiaoming (Sean) Chen to be identified as the author(s) of this work has been asserted in accordance with law.

Registered Offices

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

The publisher and the authors make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties; including without limitation any implied warranties of fitness for a particular purpose. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for every situation. In view of on-going research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or website is referred to in this work as a citation and/or potential source of further information does not mean that the author or the publisher endorses the information the organization or website may provide or recommendations it may make. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising here from.

Library of Congress Cataloging-in-Publication Data:

Names: Byrn, Stephen R., author. | Zografi, George, author. | Chen, Xiaoming (Sean), author.

Title: Solid-state properties of pharmaceutical materials / Stephen R. Byrn, George Zografi, Xiaoming (Sean) Chen.

Description: Hoboken, NJ : John Wiley & Sons, 2017. | Includes index.

Identifiers: LCCN 2017005555 (print) | LCCN 2017008527 (ebook) | ISBN 9781118145302 (cloth) |

ISBN 9781119264446 (Adobe PDF) | ISBN 9781119264453 (ePub)

Subjects: LCSH: Solid state chemistry. | Solid dosage forms--Properties.

Classification: LCC QD478 .B96 2017 (print) | LCC QD478 (ebook) | DDC 615.1028/4--dc23

LC record available at <https://lccn.loc.gov/2017005555>

Cover images: (Background) © Mimi Haddon/Getty images; (Inset images) Aeinleng, Nunchanit et al. "Physicochemical Performances of Indomethacin in Cholesteryl Cetyl Carbonate Liquid Crystal as a Transdermal Dosage." *AAPS PharmaSciTech* 13.2 (2012); COVER. *PMC*

Cover design by Wiley

Set in 10/12pt TimesLTStd by Aptara Inc., New Delhi, India

10 9 8 7 6 5 4 3 2 1

PREFACE

The aim of this book is to illustrate the importance of understanding the fundamental solid-state properties of pharmaceutical materials during the development of solid pharmaceutical products and to lay out general strategies for the physical characterization of solids using various analytical tools. Generally, great emphasis is understandably placed on the discovery of new active pharmaceutical ingredients (API) for the cure, treatment, and prevention of various acute and chronic diseases. However, it has been firmly established that the ability to obtain successful drug products in an efficient and timely manner strongly depends on the formulation and manufacture of stable and bioavailable drugs into useful products, where various physical and chemical characteristics play an essential role. In essence, it can be said, therefore, that a “drug” is more than a molecule, rather being part of a complex mixture of materials with physical chemical characteristics that can determine therapeutic success or failure.

The book is divided into four parts. The first part focuses on the various phases or forms that solids can assume, including polymorphs, solvates/hydrates, salts, cocrystals, amorphous forms, crystal mesophases, and nanocrystals, and various issues related to their relative stability and tendencies to undergo transformations. The second part focuses on the key methods of solid-state analysis such as X-ray crystallography, X-ray powder diffraction, thermal analysis, microscopy,

vibrational spectroscopy, and solid-state NMR. The third part reviews critical physical attributes of pharmaceutical materials, mainly related to drug substances, including particle size/surface area, hygroscopicity, mechanical properties, solubility, and physical and chemical stability. The fourth part of the book builds on the first three parts to illustrate how an understanding of the various properties of pharmaceutical materials may be used for (1) the rational selection of drug solid form, (2) the analysis of mixtures of various solid forms within the drug substance and the drug product, (3) establishing rational protocols and strategies for carrying out efficient and successful product development, and (4) applications of appropriate manufacturing and control procedures, using Quality by Design, and other strategies that lead to safe and effective products with a minimum of resources and time.

Furthermore, we have attempted to design this book in such a way that it can be used by preformulation and formulation scientists, process engineers, analytical chemists, quality assurance and quality control managers, regulators, and other researchers, who all contribute to the drug development process. We hope that by presenting a mixture of fundamental solid-state science and its practical applications to the drug development process we will have helped all involved to gain a greater perspective of the importance of both aspects.

ACKNOWLEDGMENTS

Stephen Byrn credits his wife, Sally, and his family, without whom this would not have been possible.

George Zografi would like to thank his wife, Dorothy, and his family for their continuous support throughout his professional career.

Xiaoming (Sean) Chen is very grateful for the love and support from his wife, Feifei Tian, and his sons, in the preparation of this book.

We extend our deep appreciation to Bob Esposito, Kshitija Iyer, Purvi Patel, Michael Leventhal and Melissa Yanuzzi at John Wiley & Sons, Inc., and Suresh Srinivasan at Aptara, who have been supportive and patient during the preparation of this book.

SOLID-STATE PROPERTIES OF PHARMACEUTICAL MATERIALS

CONTENTS

Preface	xi
Acknowledgments	xiii
1 Solid-State Properties and Pharmaceutical Development	1
1.1 Introduction, 1	
1.2 Solid-State Forms, 1	
1.3 ICH Q6A Decision Trees, 6	
1.4 “Big Questions” for Drug Development, 6	
1.5 Accelerating Drug Development, 9	
1.6 Solid-State Chemistry in Preformulation and Formulation, 11	
1.7 Learning Before Doing and Quality by Design, 14	
1.8 Performance and Stability in Pharmaceutical Development, 17	
1.9 Moisture Uptake, 18	
1.10 Solid-State Reactions, 19	
1.11 Noninteracting Formulations: Physical Characterizations, 19	
References, 20	
2 Polymorphs	22
2.1 Introduction, 22	
2.2 How are Polymorphs Formed?, 22	
2.3 Structural Aspect of Polymorphs, 23	
2.4 Physical, Chemical, and Mechanical Properties, 24	
2.5 Thermodynamic Stability of Polymorphs, 27	
2.6 Polymorph Conversion, 32	
2.7 Control of Polymorphs, 34	
2.8 Polymorph Screening, 35	
2.9 Polymorph Prediction, 36	
References, 36	
3 Solvates and Hydrates	38
3.1 Introduction, 38	
3.2 Pharmaceutical Importance of Hydrates, 38	

3.3	Classification of Pharmaceutical Hydrates, 40	
3.4	Water Activity, 42	
3.5	Stoichiometric Hydrates, 43	
3.6	Nonstoichiometric Hydrates, 44	
3.7	Hydration/Dehydration, 45	
3.8	Preparation and Characterization of Hydrates and Solvates, 45	
	References, 46	
4	Pharmaceutical Salts	48
4.1	Introduction, 48	
4.2	Importance of Pharmaceutical Salts, 48	
4.3	Weak Acid, Weak Base, and Salt, 49	
4.4	pH-Solubility Profiles of Ionizable Compounds, 51	
4.5	Solubility, Dissolution, and Bioavailability of Pharmaceutical Salts, 53	
4.6	Physical Stability of Pharmaceutical Salts, 56	
4.7	Strategies for Salt Selection, 57	
	References, 59	
5	Pharmaceutical Cocrystals	60
5.1	Introduction, 60	
5.2	Cocrystals and Crystal Engineering, 60	
5.3	Solubility Phase Diagrams for Cocrystals, 62	
5.4	Preparation of Cocrystals, 63	
5.5	Dissolution and Bioavailability of Cocrystals, 64	
5.6	Comparison of Pharmaceutical Salts and Cocrystals, 66	
	References, 68	
6	Amorphous Solids	69
6.1	Introduction, 69	
6.2	The Formation of Amorphous Solids, 70	
6.3	Methods of Preparing Amorphous Solids, 71	
6.4	The Glass Transition Temperature, 72	
6.5	Structural Features of Amorphous Solids, 75	
6.6	Molecular Mobility, 77	
6.7	Mixtures of Amorphous Solids, 84	
	References, 87	
7	Crystal Mesophases and Nanocrystals	89
7.1	Introduction, 89	
7.2	Overview of Crystal Mesophases, 89	
7.3	Liquid Crystals, 90	
7.4	Conformationally Disordered (Condis) Crystals, 95	
7.5	Plastic Crystals, 95	
7.6	Nanocrystals, 96	
	References, 97	
8	X-Ray Crystallography and Crystal Packing Analysis	99
8.1	Introduction, 99	
8.2	Crystals, 99	
8.3	Miller Indices and Crystal Faces, 99	
8.4	Determination of the Miller Indices of the Faces of a Crystal, 101	

8.5	Determination of Crystal Structure, 103	
	References, 106	
9	X-Ray Powder Diffraction	107
9.1	Introduction, 107	
9.2	X-Ray Powder Diffraction of Crystalline Materials, 107	
9.3	Qualitative Analysis of Crystalline Materials, 109	
9.4	Phase Transformations, 110	
9.5	Quantitative Phase Analysis Using XRPD, 111	
9.6	Solving Crystal Structures Using Powder X-Ray Diffraction, 114	
9.7	X-Ray Diffraction of Amorphous and Crystal Mesophase Forms, 116	
9.8	Pair Distribution Function, 117	
9.9	X-Ray Diffractometers, 119	
9.10	Variable Temperature XRPD, 121	
	References, 122	
10	Differential Scanning Calorimetry and Thermogravimetric Analysis	124
10.1	Introduction, 124	
10.2	The Basics of Differential Scanning Calorimetry, 124	
10.3	Thermal Transitions of Pharmaceutical Materials, 125	
10.4	DSC Instrumentation, 128	
10.5	Thermogravimetric Analysis, 132	
10.6	Operating a TGA Instrument, 133	
10.7	Evolved Gas Analysis, 133	
10.8	Applications of DSC and TGA, 134	
10.9	Summary of Using DSC and TGA, 139	
	References, 140	
11	Microscopy	142
11.1	Introduction, 142	
11.2	Light Microscopy, 142	
11.3	Polarized Light Microscopy, 144	
11.4	Thermal Microscopy, 144	
11.5	Functionality of the Light Microscope, 145	
11.6	Digital Microscope, 146	
11.7	Application of Light Microscopy to Pharmaceutical Materials, 146	
11.8	Scanning Electron Microscope, 153	
11.9	Environmental Scanning Electron Microscopy, 155	
11.10	Atomic Force Microscopy, 155	
	References, 157	
12	Vibrational Spectroscopy	159
12.1	Introduction, 159	
12.2	The Nature of Molecular Vibrations, 160	
12.3	Fourier Transformed Infrared Spectroscopy, 161	
12.4	Material Characterization by FT-IR Spectroscopy, 162	
12.5	FT-IR Instrumentation, 164	
12.6	Diffuse Reflectance FT-IR, 165	
12.7	Attenuated Total Reflectance FT-IR, 166	
12.8	FT-IR Microscopy, 167	
12.9	Near Infrared Spectroscopy, 168	

- 12.10 Raman Spectroscopy, 170
- 12.11 Raman Instrumentation and Sampling, 171
- 12.12 Raman Microscope, 173
- 12.13 Terahertz Spectroscopy, 175
- 12.14 Comparison of FT-IR, NIR, Raman, and Terahertz Spectroscopy, 176
- References, 178

13 Solid-State NMR Spectroscopy 180

- 13.1 Introduction, 180
- 13.2 An Overview of Solid-State ^{13}C CP/MAS NMR Spectroscopy, 180
- 13.3 Solid-State NMR Studies of Pharmaceuticals, 185
- 13.4 Phase Identification in Dosage Forms, 186
- 13.5 Other Basic Solid-State NMR Experiments Useful for Pharmaceutical Analysis, 189
- 13.6 Determination of the Domain Structure of Amorphous Dispersions Using Solid-State NMR, 192
- References, 196

14 Particle and Powder Analysis 197

- 14.1 Introduction, 197
- 14.2 Particles in Pharmaceutical Systems, 197
- 14.3 Particle Size and Shape, 199
- 14.4 Particle Size Distribution, 200
- 14.5 Dynamic Light Scattering, 202
- 14.6 Zeta Potential, 203
- 14.7 Laser Diffraction, 205
- 14.8 Dynamic Image Analysis, 206
- 14.9 Sieve Analysis, 208
- 14.10 Bulk Properties of Pharmaceutical Particulates and Powders, 208
- 14.11 Surface Area Measurement, 209
- References, 211

15 Hygroscopic Properties of Solids 213

- 15.1 Introduction, 213
- 15.2 Water Vapor Sorption–Desorption, 214
- 15.3 Water Vapor Sorption Isotherms, Relative Humidity, and Water Activity, 214
- 15.4 Measurement of Water Content and Water Vapor Sorption/Desorption Isotherms, 216
- 15.5 Modes of Water Vapor Sorption, 218
- References, 229

16 Mechanical Properties of Pharmaceutical Materials 231

- 16.1 Introduction, 231
- 16.2 Stress and Strain, 231
- 16.3 Elasticity, 232
- 16.4 Plasticity, 233
- 16.5 Viscoelasticity, 234
- 16.6 Brittleness, 235
- 16.7 Hardness, 236
- 16.8 Powder Compression, 237
- 16.9 Powder Compression Models and Compressibility, 238
- 16.10 Compactibility and Tensile Strength, 239
- 16.11 Effect of Solid Form on Mechanical Properties, 239
- 16.12 Effect of Moisture on Mechanical Properties, 242
- 16.13 Methods for Testing Mechanical Properties: Beam Bending, 243

16.14	Nanoindentation, 246	
	References, 247	
17	Solubility and Dissolution	249
17.1	Introduction, 249	
17.2	Principle Concepts Associated with Solubility, 249	
17.3	Prediction of Aqueous Drug Solubility, 250	
17.4	Solubility of Pharmaceutical Solid Forms, 252	
17.5	Solubility Determination Using the Shake Flask Method, 253	
17.6	High Throughput Screening of Solubility, 254	
17.7	Solubility Measurement of Metastable Forms, 255	
17.8	Kinetic Solubility Measurement, 256	
17.9	Solubility Determination of Drugs in Polymer Matrices, 256	
17.10	Dissolution Testing, 257	
17.11	Nonsink Dissolution Test, 260	
17.12	Intrinsic Dissolution Studies, 262	
	References, 263	
18	Physical Stability of Solids	265
18.1	Introduction, 265	
18.2	Underlying Basis for Physical Instability in Pharmaceutical Systems, 266	
18.3	Disorder in Crystals, 267	
18.4	Examples of the Role of Process-Induced Disorder in Solid-State Physical Instability in Pharmaceutical Systems, 274	
18.5	Considerations in Evaluating Solid-State Physical Stability, 276	
	References, 277	
19	Chemical Stability of Solids	279
19.1	Introduction, 279	
19.2	Examples of Chemical Reactivity in the Solid State, 279	
19.3	Some General Principles that Establish the Rate of Chemical Reactions in Solution, 282	
19.4	The Role of Crystal Defects in Solid-State Reactions, 286	
19.5	Chemical Reactivity in the Amorphous Solid State, 290	
19.6	Chemical Reactivity and Process-Induced Disorder, 292	
19.7	The Effects of Residual Water on Solid-State Chemical Reactivity, 294	
19.8	Drug–Excipient Interactions, 298	
19.9	Summary, 300	
	References, 300	
20	Solid-State Properties of Proteins	302
20.1	Introduction, 302	
20.2	Solution Properties of Proteins, 302	
20.3	Amorphous Properties of Proteins, 306	
20.4	Crystalline Properties of Proteins, 307	
20.5	Local Molecular Motions and the Dynamical Transitional Temperature, T_d , 308	
20.6	Solid-State Physical and Chemical Stability of Proteins, 310	
20.7	Cryoprotection and Lyoprotection, 311	
	References, 311	
21	Form Selection of Active Pharmaceutical Ingredients	313
21.1	Introduction, 313	
21.2	Form Selection, 313	

21.3	Amorphous form Screening, 315	
21.4	Salt Selection, 316	
21.5	Cocrystal Screening, 318	
21.6	Polymorph Screening, 320	
21.7	Slurrying, 321	
21.8	High Throughput Screening, 322	
21.9	Crystallization in Confined Space, 323	
21.10	Nonsolvent-Based Polymorph Screening, 325	
21.11	Polymer-Induced Heteronucleation, 325	
21.12	Physical Characterization, 326	
21.13	Thermodynamic Stability and form Selection, 327	
	References, 328	
22	Mixture Analysis	331
22.1	Introduction, 331	
22.2	Limitations of Wet Chemistry, 331	
22.3	Pharmaceutical Analysis in the Solid State, 332	
22.4	Measurement of Amorphous Content, 335	
22.5	Detection of the Degree of Crystallinity, 337	
22.6	Quantification of Mixtures of Polymorphs, 339	
22.7	Salt and Free form Composition, 340	
22.8	Process Analytical Technology, 342	
	References, 348	
23	Product Development	351
23.1	Chemistry, Manufacture, and Control, 351	
23.2	Preformulation, 353	
23.3	Drug Excipient Compatibility, 354	
23.4	Solid Dispersions, 355	
23.5	Abuse-Deterrent Dosage Forms, 361	
23.6	Drug-Eluting Stents, 363	
23.7	Dry Powder Inhalers (DPI), 365	
23.8	Lyophilization and Biopharmaceutical Products, 368	
	References, 372	
24	Quality by Design	375
24.1	Introduction, 375	
24.2	Quality by Design Wheel, 375	
24.3	Learning Before Doing, 379	
24.4	Risk-Based Orientation, 380	
24.5	API Attributes and Process Design, 381	
24.6	Development and Design Space, 381	
24.7	Process Design: Crystallization, 385	
24.8	Phase Transformations During Wet Granulation, 386	
24.9	Dissolution Tests with an IVIVC for Quality by Design, 387	
24.10	Conclusion, 388	
	References, 388	
	Index	389

SOLID-STATE PROPERTIES AND PHARMACEUTICAL DEVELOPMENT

1.1 INTRODUCTION

Solid-state chemistry and the solid-state properties of pharmaceutical materials play an ever increasing and important role in pharmaceutical development. There is much more emphasis on physical characterization since the release of the International Committee on Harmonization (ICH) Q6A guidance on specifications. This guidance directs the scientist to determine what solid form is present in the drug substance (active pharmaceutical ingredient [API]) and drug product. It directs the manufacturer to “know what they have.” Additionally, the ICH Q8 guidance on development and the ICH Q9 guidance on risk management require a firm understanding of how the medicine was developed and any risks involved.

There are many more poorly soluble drugs under development. In many cases, the solid form of the API and the solid form and formulation in the drug product determine apparent solubility that in turn determines blood levels. That is, the formulation determines bioavailability and therapeutic response. In these cases, it is even more important to physically characterize the API form and the formulations. Furthermore, the vast majority of medicines (drug products) are solids and those drug products that are not solids often start with solid APIs. In addition to solubility and bioavailability, the solid form may affect stability, flow, compression, hygroscopicity, and a number of other properties.

This book focuses on solid-state properties of pharmaceutical materials and methods of determining these properties. The authors have made every effort to include examples and

case studies in order to illustrate the importance of knowing what you have. This book will focus on solid-state properties and general strategies for physical characterization. Case studies and practical examples will be emphasized. In many respects, this book will illustrate that a medicine is more than a molecule. Additional goals include providing a full physical/analytical/operational definition of the different solid forms as well as other terms frequently used in pharmaceutical materials science including: polymorph, solvate, amorphous form, habit, nucleation, transformation, dissolution, solubility, and stability.

1.2 SOLID-STATE FORMS

Pharmaceutical materials can exist in a crystalline or amorphous state. Figure 1.1 illustrates the crystalline state as a perfectly ordered solid with molecules (circles) packed in an orderly array. Figure 1.1 illustrates an amorphous material as a disordered material with only short-range order. Crystalline materials give an X-ray diffraction pattern because Bragg planes exist in the material (see Figure 1.2). Amorphous materials do not give a diffraction pattern (Figure 1.2). Of course, there are many interesting cases where a pharmaceutical material shows an intermediate degree of order falling somewhere between the highly ordered crystalline state and the disordered amorphous state. From a thermodynamic point of view, crystalline materials are more stable but the rate of transformation of amorphous materials to crystalline materials can be highly variable [1].




FIGURE 1.1 Idealized view of crystalline (left panel) and amorphous (right panel) material. In this two-dimensional figure, the molecules are viewed as circles.

Crystals of a pharmaceutical material from different sources can vary greatly in their size and shape. Typical particles in different samples may resemble, for example, needles, rods, plates, and prisms. Such differences in shape are collectively referred to as differences in morphology. This term merely acknowledges the fact of different shapes. It does not distinguish among the many possible reasons for the different

shapes. Naturally, when different compounds are involved, different crystal shapes would be expected as a matter of course. When batches of the same substance display crystals with different morphology, however, further work is needed to determine whether the different shapes are indicative of polymorphs, solvates, or just habits. Because these distinctions can have a profound impact on drug performance, their




FIGURE 1.2 X-ray diffraction pattern of three samples, crystalline, low crystallinity, and amorphous.

careful definition is very important to our discourse. At this time, only brief definitions are presented.

- **Polymorphs:** When two crystals have the *same chemical composition* but *different internal structure* (molecular packing), they are polymorphic modifications, or polymorphs (think of the three forms of carbon: diamond, graphite, and fullerenes). Polymorphs can result from different molecular packing, different molecular conformation, different tautomeric structure, or combinations of these.
- **Solvates:** These crystal forms, in addition to containing molecules of the same given substance, also contain *molecules of solvent* regularly incorporated into a unique structure (think of wet, setting plaster: $\text{CaSO}_4 + 2\text{H}_2\text{O} \rightarrow \text{CaSO}_4 \cdot 2\text{H}_2\text{O}$).
- **Habits:** Crystals are said to have different habits when samples have the *same chemical composition* and the *same crystal structure* (i.e., the same polymorph and unit cell) but display different shapes (think of snowflakes).

Together, these solid-state physical modifications of a compound are referred to as crystalline forms. When differences between early batches of a substance are found by microscopic examination, for example, a reference to “form” is particularly useful in the absence of information that allows the more accurate description of a given variant batch (i.e., polymorph, solvate, habit, or amorphous material). The term pseudopolymorphism is applied frequently to designate solvates. These solid-state modifications have different physical properties.

To put these important definitions into a practical context, we consider two cases (aspirin and flufenamic acid) in which a drug was crystallized from several different solvents and different-shaped crystals resulted in each experiment. Although sometimes dramatically different shapes were obtained upon changing solvents for the various crystallizations, the final interpretations in the two cases are different. For aspirin, X-ray powder diffraction showed that all crystals regardless of shape had the same diffraction pattern. Thus, the different shaped crystals are termed crystal habits. For flufenamic acid, the different shaped crystals had different X-ray powder diffraction patterns. Subsequent analysis showed that the crystals did not contain solvent. Thus these different crystals are polymorphs.

Further analysis of the crystals from this case provides the single crystal structure. The single crystal structure gives the locations of the atoms relative to a hypothetical unit cell. The unit cell is the smallest building block of a crystal. Figure 1.3 shows the unit cell of Form I of flufenamic acid. This unit cell contains four flufenamic acid molecules. Figure 1.4 shows a space-filling model of the contents of the flufenamic acid Form I unit cell. This figure illustrates Kitaigorodskii’s close-packing theory, which requires that the molecules pack to minimize free volume [2].

Amorphous materials will be discussed in Chapter 6. In this introductory chapter as mentioned briefly above, amorphous materials have no long range order and are thermodynamically metastable. An amorphous solid is characterized by a unique glass transition temperature T_g , the temperature at which it changes from a glass to a supercooled liquid or rubbery state. When T rises above T_g , the rigid solid can





FIGURE 1.3 Single crystal structure the Form I polymorph of flufenamic acid (structure shown on the right panel).





FIGURE 1.4 Space filling drawing of the unit cell of flufenamic acid Form I.

flow and the corresponding increase in molecular mobility can result in crystallization or increased chemical reactivity of the solid. Several historic papers describe some additional details of amorphous materials. Pikal and coworkers at Eli Lilly showed that amorphous materials can have lower chemical stability [3], and Fukuoka et al. showed amorphous materials had a tendency to crystallize [4]. Nevertheless, in some cases, amorphous forms have been historically used as products. An excellent example is novobiocin [5], which exists in a crystalline and an amorphous form. The crystalline form is poorly absorbed and does not provide therapeutic blood levels; in contrast, the amorphous form is readily absorbed and is therapeutically active. Further studies show that the solubility rate of the amorphous form is 70 times greater than the crystalline form in 0.1 N HCl at 25°C when particles <10 micron are used.



It is possible to make a “top 10” list of the differences between crystalline and amorphous materials. Crystalline materials have the following characteristics:

1. higher purity,
2. More physically and chemically stable, *crystalline hydrate* > *anhydrous crystal* > *amorphous*
3. lower solubility,
4. narrow and (usually) higher melting point range,
5. harder,
6. brittle – slip and cleavage,
7. directionally dependent properties – anisotropy,
8. less compressible,
9. better flow and handling characteristics, and
10. less hygroscopic.

From this list, it is clear that crystalline materials are generally more desirable unless they are so insoluble that they cannot be used as medicines.

Not only do polymorphs show different X-ray powder diffraction patterns but they also have different unit cells, and different properties including thermal properties [6]. Figure 1.5 shows the different crystal packing of the Forms I and II of sulfathiazole.

Additionally, polymorphs are characterized as monotropic or enantiotropic depending upon their thermal properties [9, 10].

- Monotropic polymorphs exist if the transition temperature between forms is greater than the melt. In monotropic polymorphs, one form is most stable throughout the temperature range.
- Enantiotropic polymorphs exist if the transition temperature between forms occurs before melting. In this case, one form is more stable at one temperature. At a




FIGURE 1.5 Crystal packing and unit cells (grey) of Forms I (left panel) and II (right panel) of sulfathiazole. The grey and black molecules in Form I indicate two unrelated molecules in the asymmetric unit. *Source:* Kruger and Gafner, 1971 [7, 8]. Redrawn from data published.

different temperature the other form is most stable. For flufenamic acid, Form I is most stable above the transition temperature of 42°C and Form III is most stable below the transition temperature. Practically, this means that slurring at room temperature will convert Form I to Form III.

Crystalline solvates contain solvents regularly incorporated into the crystal lattice. When the solvent is water the solid form is called a hydrate. Solvates and hydrates do not have the same composition as unsolvated materials. Solvates and hydrates are sometimes referred to as pseudopolymorphs or solvatomorphs. Interestingly, it is possible for solvates and hydrates to be polymorphic. In such a case one has polymorphic solvates. Kuhnert Brandstatter in her 1971 book showed photomicrographs of 16 solvates of estradiol [11]. Figure 1.6 shows the crystal structure of caffeine monohydrate. The crystal of caffeine is built up by stacking the layers shown in Figure 1.6 on top of each other. Thus the hydrate molecules are in tunnels in this solid form.

It is important to note that the FDA (Food and Drug Administration) has defined polymorphs as “different crystalline forms of the same drug substance. This may include solvation or hydration products (also known as pseudopolymorphs) and amorphous forms. Per the current regulatory scheme, different polymorphic forms are considered the same active ingredients.” Thus, for purposes of registration, scientists are directed to define polymorphs more broadly to include amorphous forms, solvates, and hydrates.

Cocrystals, that is, two component crystals, are another solid material of interest. Like solvates, the new crystalline




FIGURE 1.6 Projection of the crystal structure of caffeine hydrate on the *ab* plane. Source: Burger and Ramberger, 1979 [9, 10]. Reproduced with the permission of Springer.





FIGURE 1.7 Crystal structure of a cocrystal (2-methoxy-4-nitrophenol-4-(dimethylamino)pyridine (2:1)). The unit cell parameters are $a = 6.880$, $b = 38.40$, $c = 8.454$, and the space group is $Pna2_1$. Source: Burger and Ramberger, 1979 [9, 10]. Reproduced with the permission of Springer.

structure imparts different properties including solubility, stability, and mechanical properties to the material. Of special interest are cocrystals with altered solubility or stability. Figure 1.7 shows the crystal structure of a cocrystal of phenol and 2-methoxy-4-nitrophenol-4-(dimethylamino)pyridine (2:1) [12]. The FDA has recently released a draft guidance defining cocrystals as “Solids that are crystalline materials composed of two or more molecules in the same crystal lattice.”

Pharmaceutical salts are substances formed by a reaction of an acid and a base. The FDA has suggested the following definition of salts as “Any of numerous compounds that result from replacement of part or all of the acid hydrogen of an acid by a metal or a radical acting like a metal: an ionic or electrovalent crystalline compound. Per the current regulatory scheme, different salt forms of the same active moiety are considered different active ingredients.” When a carboxylic acid reacts with an amine a salt is typically formed (Scheme 1.1). However, the degree of proton transfer can vary depending on the acidity and basicity of the reacting groups. The FDA definition seems to encompass all of these materials.



SCHEME 1.1